Clinical Trials Logo

Filter by:
NCT ID: NCT05924841 Recruiting - Clinical trials for Small Cell Lung Cancer

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer

Start date: November 10, 2023
Phase: Phase 2
Study type: Interventional

This phase II study is designed to investigate the efficacy and safety of BL-B01D1 monotherapy, SI-B003 monotherapy, and BL-B01D1+SI-B003 combination therapy in patients with extensive-stage small cell lung cancer.

NCT ID: NCT05924776 Not yet recruiting - Clinical trials for Advanced Ovarian Cancer

Plasmodium Immunotherapy for Advanced Ovarian Cancer

Start date: April 20, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The main purpose of this study is to evaluate the safety and effectiveness of Plasmodium immunotherapy in the treatment of advanced ovarian cancer. This study plans to enroll 30 patients with advanced ovarian cancer. Each patient is inoculated with Plasmodium vivax 1-5 × 10^6, observe the time when the parasite is detected in the peripheral blood of the subjects after the inoculation of Plasmodium, the change of the parasite density in the peripheral blood of the whole treatment cycle and the control effect of the drug on the parasite density, the main clinical symptoms and signs, laboratory test indicators, immunological test indicators and changes in the quality of life. To evaluate the safety and tolerance of the subjects to Plasmodium immunotherapy, as well as the changes of tumor related indicators and immunological indicators.

NCT ID: NCT05924750 Recruiting - Clinical trials for Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Start date: August 2, 2023
Phase: Phase 1
Study type: Interventional

Ia: To observe the safety and tolerability of BL-M11D1 in patients with relapsed/refractory acute myeloid leukemia to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of BL-M11D1. Ib: Further observe the safety and tolerability of BL-M11D1 at the recommended dose in phase Ia to determine the recommended dose in phase II clinical study (RP2D).

NCT ID: NCT05924620 Completed - Clinical trials for Primary Aldosteronism

Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism

Start date: June 21, 2023
Phase: Phase 4
Study type: Interventional

To study the efficacy and safety of finerenone in patients with primary aldosteronism

NCT ID: NCT05924373 Recruiting - Periodontitis Clinical Trials

Human Dental Pulp Mesenchymal Stem Cells for the Treatment of Chronic Periodontitis Patients

Start date: November 27, 2023
Phase: Phase 2
Study type: Interventional

The primary objective:To evaluate the efficacy of different administration protocols of human dental pulp mesenchymal stem cells for the treatment of chronic periodontitis patients. The secondary objective:To evaluate the safety of different administration protocols of human dental pulp mesenchymal stem cells for the treatment of chronic periodontitis patients. The exploratory objective:To investigate the effects of human dental pulp mesenchymal stem cells on biomarkers in gingival crevicular fluid in chronic periodontitis patients.

NCT ID: NCT05924308 Recruiting - Clinical trials for Post-stroke Mild Cognitive Impairment

Acupuncture Therapy for Post-stroke Mild Cognitive Impairment: a Randomized Controlled Trial

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

1. On the basis of previous studies, standardized randomized controlled clinical trials were conducted to observe the efficacy and safety of acupuncture in the treatment of mild cognitive impairment after stroke using the international rating scale, and the clinical experience was transformed into evidence. 2. According to the clinical outcomes reported by patients, the differences between Chinese and western scales in evaluating mild cognitive impairment after stroke were compared. On the basis of "disease differentiation, syndrome differentiation and meridian differentiation", the syndrome differentiation and treatment system of mild cognitive impairment after stroke was preliminarily constructed, and the TCM syndrome prediction model was improved.

NCT ID: NCT05924256 Recruiting - Clinical trials for Advanced Salivary Gland Carcinoma

A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing

Start date: July 26, 2023
Phase: Phase 2
Study type: Interventional

This is a single-center, open-label, phase 2 study to evaluate the efficacy and safety of target therapy for patients with relapsed/metastastic salivary gland carcinoma based on molecular typing.

NCT ID: NCT05923931 Recruiting - Heat Stroke Clinical Trials

Non-inferiority Study of the Effect of Non-cooling Blanket on Body Temperature in Patients With Heat Stroke

Start date: May 28, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test the cooling effect of cooling blanket in patients with heat stroke. The main questions it aims to answer are: - the cooling rate of cooling blanket in patients with heat stroke - the relationship between cooling blanket and outcomes in patients with heat stroke Participants will accept the cooling blanket or non-cooling blanket according to the randomization group. Researchers will compare cooling rate and outcomes to see if the cooling blanket can accelerate the cooling speed and improve the prognosis of patients in heat stroke.

NCT ID: NCT05923905 Recruiting - Clinical trials for Sporadic and Familial Amyotrophic Lateral Sclerosis

Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients

FB1006
Start date: January 18, 2023
Phase: Phase 4
Study type: Interventional

This is a randomized double-blind controlled exploratory clinical study to evaluate the efficacy and safety of FB1006 in the treatment of amyotrophic lateral sclerosis (ALS) patients.

NCT ID: NCT05923892 Recruiting - Clinical trials for Irritable Bowel Syndrome of Diarrhea Type (IBS-D)

Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type

Start date: August 2, 2023
Phase: Phase 2
Study type: Interventional

This is a A Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Trial to Evaluate the Efficacy and Safety of Different Doses of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea type (IBS-D).The trial is mainly divided into three periods: screening period, treatment period and follow-up period.